2Invest AG

2Invest AG maintains a strong liquidity position, as evidenced by a current ratio of 28.53, indicating that its current assets significantly exceed its current liabilities. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure with no leverage. This liquidity is supported by a total equity of EUR 86.15 million and total assets of EUR 88.05 million. Profitability metrics show a return on equity (ROE) of 3.94% and a return on assets (ROA) of 3.86%. These figures are below the typical thresholds for high-growth investment holding companies, which often aim for ROE and ROA above 10%. The company's net income of EUR 3.40 million and operating income of EUR 8.13 million suggest modest earnings relative to its asset base. The company's revenue is concentrated in the biotechnology, life science, IT, and natural resources sectors, with no disclosed geographic breakdown. This concentration may expose the company to sector-specific risks, particularly in biotechnology and IT, which are subject to rapid innovation cycles and regulatory changes. The lack of geographic diversification could also increase exposure to regional economic downturns. Growth trajectory appears stable, with the company reporting operating cash flow of EUR 12.85 million and free cash flow of EUR 3.40 million. Analyst estimates indicate a last actual revenue of EUR 68.42 million and an EPS of EUR 9.57. While these figures suggest a solid cash flow position, the absence of forward-looking guidance or projected growth rates makes it difficult to assess future performance. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. The company's capital structure is free of dilutionary instruments, and its equity base is robust. However, the absence of long-term debt could limit its ability to leverage growth opportunities in the future. Recent events include the company's rebranding from 4Basebio AG to 2Invest AG, reflecting a strategic shift from biotechnology to a broader investment holding model. No recent filings or transcripts were provided in the input data, so further details on recent corporate actions or strategic initiatives are not available.